Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Oct 23;17(1):385.
doi: 10.1186/s13023-022-02492-6.

Efficacy of ketogenic diet in CDKL5-related epilepsy: a single arm meta-analysis

Jie Zhang  1 , Jiayi Ma  1 , Xuting Chang  1 , Pengxia Wu  1 , Shangru Li  1 , Ye Wu  2
Affiliations
Meta-Analysis

Efficacy of ketogenic diet in CDKL5-related epilepsy: a single arm meta-analysis

Jie Zhang et al. Orphanet J Rare Dis. .

Abstract

Background: Drug-resistant epilepsy is one of the most important features of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. The ketogenic diet (KD) may be effective for patients with CDKL5-related epilepsy, but there is little high-quality evidence to confirm the efficacy. This meta-analysis investigated the efficacy and safety of KD in CDKL5-related epilepsy.

Methods: The PubMed, Embase, Web of Science, Cochrane Library, WanFang, CNKI and VIP databases were searched for relevant studies published up to January 1, 2022. Two reviewers independently screened the literature according to inclusion and exclusion criteria and evaluated the bias risk of the included studies. Meta-analysis was performed using Review Manager 5.3 software.

Results: A total of 12 retrospective studies involving 193 patients met the inclusion criteria. Meta-analysis revealed that the definite responder rate to KD in the treatment of CDKL5-related epilepsy was 18.0% [95% CI (0.07, 0.67)], with no statistical heterogeneity among studies (I2 = 0%, P = 0.45). The clinical responder rate was 50.5% [95% CI (0.75, 1.39)], and there was no statistical heterogeneity among all studies (I2 = 46%, P = 0.05). Subgroup analysis showed that there was no significant difference in the clinical responder rate between the two groups with seizure onset age before and after 1 month (P = 0.14). Only one study mentioned adverse reactions, and the incidence of adverse reactions was 78.3% (18/23). Constipation and vomiting were the main manifestations, implying a high incidence of gastrointestinal adverse reactions.

Conclusions: The definite responder rate to KD in CDKL5-related epilepsy was 18%, and the gastrointestinal adverse reactions were probably common in these patients. All the studies included in the meta-analysis were retrospective, and most of them had small sample sizes. Additional high-quality studies are needed to confirm the efficacy and tolerance of KD in CDKL5-related epilepsy.

Keywords: CDKL5; Epilepsy; Ketogenic diet; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Searching strategy of literature
Fig. 2
Fig. 2
Flow chart of literature screening
Fig. 3
Fig. 3
Funnel plot of the responder rate
Fig. 4
Fig. 4
Forest plot of definite responder rate
Fig. 5
Fig. 5
Forest plot of clinical responder rate
Fig. 6
Fig. 6
Forest plot of clinical responder rate in subgroup analysis (onset age before or after 1 month)
See this image and copyright information in PMC

References

    1. Tao J, Van Esch H, Hagedorn-Greiwe M, et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet. 2004;75:1149–1154. doi: 10.1086/426460. - DOI - PMC - PubMed
    1. Lin C, Franco B, Rosner MR. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet. 2005;14:3775–3786. doi: 10.1093/hmg/ddi391. - DOI - PubMed
    1. Bahi-Buisson N, Bienvenu T. CDKL5-related disorders: from clinical description to molecular genetics. Mol Syndromol. 2012;2:137–152. doi: 10.1159/000331333. - DOI - PMC - PubMed
    1. Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019;97:18–25. doi: 10.1016/j.pediatrneurol.2019.02.015. - DOI - PMC - PubMed
    1. Fuchs C, Trazzi S, Torricella R, et al. Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. Neurobiol Dis. 2014;70:53–68. doi: 10.1016/j.nbd.2014.06.006. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts